| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.044 | 0.8 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |